Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000557544 | SCV000655210 | likely benign | Tumor predisposition syndrome 3 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000563209 | SCV000674397 | likely benign | Hereditary cancer-predisposing syndrome | 2017-04-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001697382 | SCV000727804 | likely benign | not provided | 2020-05-08 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000563209 | SCV002527177 | likely benign | Hereditary cancer-predisposing syndrome | 2022-02-04 | criteria provided, single submitter | curation | |
Ce |
RCV001697382 | SCV004160996 | likely benign | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | POT1: BP4, BP7 |
Prevention |
RCV003945312 | SCV004757213 | likely benign | POT1-related condition | 2021-10-18 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |